title: Induction of membrane-associated interleukin 1 alpha (IL-1 alpha) by synergistic activation of human blood monocytes with interferon gamma and muramyl dipeptide analog.
abstract: Human blood monocytes isolated by centrifugal elutriation from healthy donors were tested for ability to produce membrane-associated IL-1 in response to activation stimuli such as various types of interferons (alpha, beta and gamma) and/or synthetic des-methyl muramyl dipeptide (norMDP). When monocytes were treated with norMDP or lipopolysaccharide (LPS) for 16 hr, they released IL-1 into their culture supernatant. When these activated monocytes were fixed with paraformaldehyde (PFA), they stimulated blastogenic responses of C3H/HeJ mouse thymocytes to PHA, suggesting that membrane-associated IL-1 could be induced by norMDP or LPS. Membrane-associated IL-1 was also found to be induced by the synergistic actions of suboptimal concentrations of rIFN-gamma and nor MDP, but not of rIFN-alpha A or rIFN-beta with norMDP. A specific anti-IL-1 alpha antiserum completely inhibited membrane-associated IL-1 activity, but did not affect the thymocyte-stimulating activity of fixed monocytes. IL-1 alpha was detected by fluorescence staining using the anti-IL-1 alpha antiserum on monocytes fixed after gamma IFN-gamma and norMDP. These results suggest that IFN-gamma may be important in expression of membrane-bound IL-1 alpha by the human blood monocytes responsible for regulation of immune responses in vivo.
authors.forename: A
authors.initials: A
authors.lastname: Okubo
authors.forename: S
authors.initials: S
authors.lastname: Sone
authors.forename: M
authors.initials: M
authors.lastname: Tanaka
authors.forename: K
authors.initials: K
authors.lastname: Fukuta
authors.forename: N
authors.initials: N
authors.lastname: Inamura
authors.forename: M
authors.initials: M
authors.lastname: Nakanishi
authors.forename: K
authors.initials: K
authors.lastname: Maeda
authors.forename: H
authors.initials: H
authors.lastname: Yanagawa
authors.forename: Y
authors.initials: Y
authors.lastname: Nishioka
authors.forename: C
authors.initials: C
authors.lastname: Yamashita
mesh_terms: D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D002462:Cell Membrane / Q000378:metabolism; D004357:Drug Synergism; D005404:Fixatives; D005557:Formaldehyde; D006801:Humans; D007106:Immune Sera / Q000494:pharmacology; D007371:Interferon-gamma / Q000008:administration & dosage / Q000494:pharmacology*; D007372:Interferons / Q000494:pharmacology; D007375:Interleukin-1 / Q000096:biosynthesis* / Q000276:immunology; D008070:Lipopolysaccharides / Q000494:pharmacology; D008213:Lymphocyte Activation; D051379:Mice; D008809:Mice, Inbred C3H; D009000:Monocytes / Q000378:metabolism*; D011108:Polymers; D011994:Recombinant Proteins
chemical_list: D005404:Fixatives; D007106:Immune Sera; D007375:Interleukin-1; D008070:Lipopolysaccharides; D011108:Polymers; D011994:Recombinant Proteins; D005557:Formaldehyde; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C037224:N-acetyl-demethylmuramyl-alanyl-isoglutamine; D007371:Interferon-gamma; D007372:Interferons; C003043:paraform